Thyroid‐associated ophthalmopathy: a practical guide to classification, natural history and management
Authors:
- 13 August 2004
- journal article
- review article
- Published by Wiley in Internal Medicine Journal
- Vol. 34 (8) , 482-491
Abstract
Thyroid−associated ophthalmopathy (TAO) is an autoimmune disorder that can be divided into three clinical subtypes: congestive, myopathic and mixed ophthalmopathy. It is probably caused by immune cross‐reactivity between orbital and thyroid antigens. The best candidate antigens are the thyrotropin receptor and the novel protein, G2s, which is now identified as a fragment of the winged helix transcription factor, FOXP1. The relationship between radioiodine therapy and TAO is controversial, with two randomised controlled trials showing a transient worsening of the eye disease after treatment. The diagnosis of TAO is a clinical one, based on the presence of specific symptoms and signs. Orbital imaging, preferably magnetic resonance imaging, is useful when the diagnosis is in doubt and in patients with suspected optic neuropathy who may benefit from early intervention. Despite their lack of specificity, orbital antibodies may add weight to the diagnosis and may potentially be a useful tool in classifying the different subtypes of TAO and in monitoring disease activity. While antibodies against G2s and the thyrotropin receptor are seen in all subtypes, those against Fp and collagen XIII may be associated with the myopathic and congestive subtypes, respectively, where Fp is the flavoprotein subunit of the mitochondrial enzyme, succinate dehydrogenase. In most patients, TAO is self‐limiting and no specific treatment is required. When treatment is indicated, glucocorticoids are the mainstay of therapy. Orbital radiotherapy improves the efficacy of glucocorticoids, but is probably less beneficial as monotherapy. Orbital surgery is best reserved for patients with ‘burnt out’ inactive disease, but urgent orbital decompression may be required for optic neuropathy. The severity and clinical activity of TAO are important in determining the need for specific treatment and the likelihood of success with medical therapy, respectively. (Intern Med J 2004; 34: 482−491)Keywords
This publication has 63 references indexed in Scilit:
- Cloning and Characterization of the Novel Thyroid and Eye Muscle Shared Protein G2s: Autoantibodies against G2s Are Closely Associated with Ophthalmopathy in Patients with Graves' HyperthyroidismThe Journal of Clinical Endocrinology & Metabolism, 2000
- Differentiation of Human Orbital Preadipocyte Fibroblasts Induces Expression of Functional Thyrotropin ReceptorThe Journal of Clinical Endocrinology & Metabolism, 1999
- Serum Antibodies against the Flavoprotein Subunit of Succinate Dehydrogenase Are Sensitive Markers of Eye Muscle Autoimmunity in Patients with Graves' HyperthyroidismThe Journal of Clinical Endocrinology & Metabolism, 1999
- A 63 kDa Skeletal Muscle Protein Associated with Eye Muscle Inflammation in Graves' Disease is Identified as the Calcium Binding Protein CalsequestrinAutoimmunity, 1999
- Immunomodulatory Treatment of Graves' OphthalmopathyThyroid®, 1998
- Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study GroupThe Journal of Clinical Endocrinology & Metabolism, 1996
- Age and gender influence the severity of thyroid‐associated ophthalmopathy: a study of 101 patients attending a combined thyroid‐eye clinicClinical Endocrinology, 1993
- Detection of TSH Receptor RNA in Cultured Fibroblasts from Patients with Graves' Ophthalmopathy and Pretibial DermopathyThyroid®, 1993
- Prednisone and Cyclosporine in the Treatment of Severe Graves' OphthalmopathyNew England Journal of Medicine, 1989
- Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for HyperthyroidismNew England Journal of Medicine, 1989